We are live on
!
Find out more
VEA
Virtus ETF Advisers Portfolio holdings
AUM
$215M
1-Year Est. Return
53.68%
This Fund
S&P 500
This Quarter
Est. Return
+0.15%
1 Year Est. Return
+53.68%
3 Year Est. Return
+121.72%
5 Year Est. Return
+144.54%
10 Year Est. Return
+633.35%
AUM
$474M
AUM Growth
+$427M
(+909%)
Cap. Flow
+$433M
Cap. Flow
% of AUM
91.18%
Top 10 Holdings %
Top 10 Hldgs %
10.55%
Holding
454
New
296
Increased
64
Reduced
55
Closed
20
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
OXLC
Oxford Lane Capital
OXLC
|
+$6.86M |
| 2 |
Barings BDC
BBDC
|
+$6.33M |
| 3 |
Oxford Square Capital
OXSQ
|
+$5.45M |
| 4 |
ECC
Eagle Point Credit Company
ECC
|
+$5.29M |
| 5 |
FS KKR Capital
FSK
|
+$5.24M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
ONCE
Spark Therapeutics, Inc. Common Stock
ONCE
|
+$2.25M |
| 2 |
ACOR
Acorda Therapeutics
ACOR
|
+$644K |
| 3 |
ARRY
Array Biopharma Inc
ARRY
|
+$605K |
| 4 |
NITE
Nightstar Therapeutics plc American Depositary Shares
NITE
|
+$603K |
| 5 |
uniQure
QURE
|
+$374K |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Financials | 23.58% |
| 2 | Real Estate | 14.99% |
| 3 | Energy | 13.55% |
| 4 | Healthcare | 12.23% |
| 5 | Materials | 8.21% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
276
Assembly Biosciences
ASMB
$506M
| $248K | 0.05% |
+1,535
| New | +$292K |
|
277
Rocket Pharmaceuticals
RCKT
$348M
| $248K | 0.05% |
16,535
-1,264
| -7% | -$22.1K |
|
278
Abeona Therapeutics
ABEO
$345M
| $247K | 0.05% |
2,064
+645
| +45% | +$108K |
|
279
Atara Biotherapeutics
ATRA
$71.2M
| $245K | 0.05% |
+488
| New | +$344K |
|
|
AMRS
280
DELISTED
Amyris Inc.
AMRS
| $242K | 0.05% |
67,863
+2,205
| +3% | +$8.68K |
|
|
SRNE
281
DELISTED
Sorrento Therapeutics, Inc.
SRNE
| $226K | 0.05% |
84,682
-23,079
| -21% | -$83.1K |
|
282
ProQR Therapeutics
PRQR
$243M
| $220K | 0.05% |
24,216
+9,291
| +62% | +$110K |
|
283
AnaptysBio
ANAB
$1.6B
| $216K | 0.05% |
+3,822
| New | +$275K |
|
284
Alibaba
BABA
$269B
| $194K | 0.04% |
1,142
+626
| +121% | +$108K |
|
|
BHVN
285
DELISTED
Biohaven Pharmaceutical Holding Company Ltd.
BHVN
| $186K | 0.04% |
4,249
-3,160
| -43% | -$178K |
|
286
Fomento Económico Mexicano
FMX
$43.3B
| $84K | 0.02% |
+868
| New | +$84K |
|
287
HDFC Bank
HDB
$119B
| $79K | 0.02% |
2,416
-776
| -24% | -$23.4K |
|
288
America Movil
AMX
$78.1B
| $77K | 0.02% |
5,303
+263
| +5% | +$3.89K |
|
289
Microsoft
MSFT
$2.84T
| $77K | 0.02% |
+575
| New | +$73K |
|
290
Bank of America
BAC
$435B
| $70K | 0.01% |
+2,421
| New | +$69.8K |
|
291
Progressive
PGR
$124B
| $61K | 0.01% |
+763
| New | +$59K |
|
292
Verizon
VZ
$194B
| $59K | 0.01% |
+1,026
| New | +$59.1K |
|
293
Mastercard
MA
$477B
| $54K | 0.01% |
203
+38
| +23% | +$9.51K |
|
294
Honeywell
HON
$77.1B
| $53K | 0.01% |
+320
| New | +$50.9K |
|
295
Clear Channel Outdoor Holdings
CCO
$1.23B
| $49K | 0.01% |
+10,420
| New | +$53.2K |
|
296
Elevance Health
ELV
$81.9B
| $49K | 0.01% |
+175
| New | +$47.8K |
|
297
American Express
AXP
$223B
| $48K | 0.01% |
+385
| New | +$45.2K |
|
298
Agilent Technologies
A
$39.1B
| $45K | 0.01% |
600
+267
| +80% | +$19.8K |
|
299
Adobe
ADBE
$89.5B
| $43K | 0.01% |
146
| – | – |
|
300
Itaú Unibanco
ITUB
$91.3B
| $43K | 0.01% |
+6,244
| New | +$39.3K |
|
Similar funds
NCM
SSA
LIWM
VFG
IAM
1M
GC
ALS
Virtus ETF Advisers's Q2 2019 Portfolio in Review
As of Q2 2019, Virtus ETF Advisers held 454 positions worth $474M, up 909% from $47M the previous quarter. Its ten largest holdings account for 11% of the portfolio.
Virtus ETF Advisers deployed $433M of net new capital in Q2 2019, opening 296 new positions and adding to 64 existing holdings. Its largest new stake was Oxford Lane Capital: 132,284 shares worth $6.67M.
By sector, the portfolio is most concentrated in Financials at 24% of assets, up from 0.73% a quarter earlier, followed by Real Estate and Energy.
On the sell side, the largest reduction was Array Biopharma Inc, an estimated $605K trimmed.
- Virtus ETF Advisers's largest Q2 2019 buy was Oxford Lane Capital: 132,284 shares worth $6.67M.
- Virtus ETF Advisers added most to Dominion Energy in Q2 2019, an estimated $2.63M increase.
- Virtus ETF Advisers's biggest Q2 2019 reduction was Array Biopharma Inc, cutting an estimated $605K.
- Virtus ETF Advisers fully exited Spark Therapeutics, Inc. Common Stock in Q2 2019, selling an estimated $2.25M.
- Virtus ETF Advisers's ten largest holdings make up 11% of its $474M portfolio in Q2 2019.
- Virtus ETF Advisers opened 296 new positions and closed 20 in Q2 2019.
- Virtus ETF Advisers's portfolio value rose 909% quarter-over-quarter to $474M.
Based on Virtus ETF Advisers's 13F filing for Q2 2019, filed 13 Aug 2019.